Items where Author is "Rochlitz, C."

2018

Tondorf, T. and Grossert, A. and Rothschild, S. I. and Koller, M. T. and Rochlitz, C. and Kiss, A. and Schaefert, R. and Meinlschmidt, G. and Hunziker, S. and Zwahlen, D.. (2018) Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed-methods study. Psycho-Oncology, 27 (6). pp. 1656-1663.

2016

Ehrbar, V. and Urech, C. and Alder, J. and Harringer, K. and Zanetti Dallenbach, R. and Rochlitz, C. and Tschudin, S.. (2016) Decision-making about fertility preservation—qualitative data on young cancer patients’ attitudes and needs. Archives of Women's Mental Health, 19 (4). pp. 695-699.

Laubli, H. and Tzankov, A. and Juskevicius, D. and Degen, L. and Rochlitz, C. and Stenner-Liewen, F.. (2016) Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder. Leukemia & Lymphoma, 57 (4). pp. 945-948.

2015

Meier-Abt, F. and Bentires-Alj, M. and Rochlitz, C.. (2015) Breast Cancer Prevention: Lessons to be Learned from Mechanisms of Early Pregnancy–Mediated Breast Cancer Protection. Cancer Research, 75 (5). pp. 803-807.

Zaman, K. and Winterhalder, R. and Mamot, C. and Hasler-Strub, U. and Rochlitz, C. and Mueller, A. and Berset, C. and Wiliders, H. and Perey, L. and Rudolf, C. B. and Hawle, H. and Rondeau, S. and Neven, P.. (2015) Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. European Journal of Cancer, 51 (10). pp. 1212-1220.

Wicki, A. and Ritschard, R. and Loesch, U. and Deuster, S. and Rochlitz, C. and Mamot, C.. (2015) Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: Production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial. International Journal of Pharmaceutics, 484 (1-2). pp. 8-15.

Conen, K. and Mosna-Firlejczyk, K. and Rochlitz, C. and Wicki, A. and Itin, P. and Arnold, A. W. and Gross, M. and Zimmermann, F. and Zippelius, A.. (2015) Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. Dermatology, 230 (1). pp. 1-4.

2014

Romer, A. and Seiler, D. and Marincek, N. and Brunner, P. and Koller, M. T. and Ng, Q. K. T. and Maecke, H. R. and Müller-Brand, J. and Rochlitz, C. and Briel, M. and Schindler, C. and Walter, M. A.. (2014) Somatostatin-based radiopeptide therapy with [(177)Lu-DOTA]-TOC versus [ (90)Y-DOTA]-TOC in neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, Vol. 41, H. 2. pp. 214-222.

2013

Bontognali, S. and Pless, M. and Brutsche, M. H. and Fischer, C. and Rochlitz, C. and Buess, M.. (2013) Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib. Onkologie, 36 (4). pp. 161-166.

Marincek, N. and Jorg, A. C. and Brunner, P. and Schindler, C. and Koller, M. T. and Rochlitz, C. and Muller-Brand, J. and Maecke, H. R. and Briel, M. and Walter, M. A.. (2013) Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors : long-term outcome of a phase I dose escalation study. Journal of translational medicine, Vol. 11 , 17. p. 17.

2012

Villard, L. and Romer, A. and Marincek, N. and Brunner, P. and Koller, M. T. and Schindler, C. and Ng, Q. K. and Macke, H. R. and Muller-Brand, J. and Rochlitz, C. and Briel, M. and Walter, M. A.. (2012) Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 30, H. 10. pp. 1100-1106.

Rajski, M. and Vogel, B. and Baty, F. and Rochlitz, C. and Buess, M.. (2012) Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS ONE, Vol. 7, H. 1 , e29743.

Mamot, C. and Ritschard, R. and Wicki, A. and Kung, W. and Schuller, J. and Herrmann, R. and Rochlitz, C.. (2012) Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. Journal of drug targeting, Vol. 20, H. 5. pp. 422-432.

Wicki, A. and Rochlitz, C.. (2012) Targeted therapies in breast cancer. Swiss medical weekly, Vol. 142 , w13550.

Mamot, C. and Ritschard, R. and Wicki, A. and Stehle, G. and Dieterle, T. and Bubendorf, L. and Hilker, C. and Deuster, S. and Herrmann, R. and Rochlitz, C.. (2012) Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. The Lancet oncology, Vol. 13, H. 12. pp. 1234-1241.

2011

Läubli, H. and Tzankov, A. and Forno, C. and Rochlitz, C. and Rothschild, S.. (2011) A prostate cancer patient presenting with bilateral subdural hematoma and a subsequent development of multiple skin metastases. Schweizer Krebsbulletin, 2011, H. 4. pp. 354-356.

Rochlitz, C. and Ruhstaller, T. and Lerch, S. and Spirig, C. and Huober, J. and Suter, T. and Buhlmann, M. and Fehr, M. and Schonenberger, A. and von Moos, R. and Winterhalder, R. and Rauch, D. and Muller, A. and Mannhart-Harms, M. and Herrmann, R. and Cliffe, B. and Mayer, M. and Zaman, K.. (2011) Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer : a multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, Vol. 22, H. 1. pp. 80-85.

Imhof, A. and Brunner, P. and Marincek, N. and Briel, M. and Schindler, C. and Rasch, H. and Macke, H. R. and Rochlitz, C. and Muller-Brand J., and Walter, M. A.. (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 29, H. 17. pp. 2416-2423.

Schmid, S. M. and Myrick, M. E. and Forrer, F. and Obermann, E. C. and Viehl, C. T. and Rochlitz, C. and Güth, U.. (2011) Sentinel lymph node biopsy in primary breast cancer : trust the radiolabeled colloid method and avoid unnecessary procedures. European journal of surgical oncology, Vol. 37, H. 3. pp. 211-216.

2010

Rajski, M. and Zanetti-Dallenbach, R. and Vogel, B. and Herrmann, R. and Rochlitz, C. and Buess, M.. (2010) IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC medicine, Vol. 8. p. 1.

2008

Salzberg, M. and Kirson, E. and Palti, Y. and Rochlitz, C.. (2008) A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie, 31 (7). pp. 362-365.

Thürlimann, B. and Bonnefoi, H. and Cameron, D. and Goldhirsch, A. and Herrmann, R. and Monnerat, C. and von Moos, R. and Pagani, O. and Perey, L. and Pestalozzi, B. and Rochlitz, C. and Suter, T.. (2008) Adjuvant therapy of HER2-positive breast cancer with trastuzumab. Senologie, Vol. 5. pp. 1-3.

Rochlitz, C.. (2008) Brustkrebs - neue Entwicklungen in Vorbeugung, Diagnostik und Behandlung. Therapeutische Umschau, Vol. 65, Nr. 4. pp. 185-186.

Gross, M. and Obermann, E. and Weinand, K. and Zimmermann, F. and Rochlitz, C.. (2008) Der aktuelle Stand beim invasiven, nicht hämatogen metastasierten Mammakarzinom. InfoOnkologie, Vol. 11. pp. 595-605.

Dummer, R. and Rochlitz, C. and Velu, T. and Acres, B. and Limacher, J. M. and Bleuzen, P. and Lacoste, G. and Slos, P. and Romero, P. and Urosevic, M.. (2008) Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Molecular therapy, Vol. 16, H. 5. pp. 985-994.

2007

Iten, F. and Muller, B. and Schindler, C. and Rochlitz, C. and Oertli, D. and Macke, H. R. and Muller-Brand, J. and Walter, M. A.. (2007) Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clinical Cancer Research, 13 (22). pp. 6696-6702.